EUVIMEDEUVIMED entdecken
Open Access

Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics

Eslam Montaser iD, Leon S Farhy iD, Boris P Kovatchev iD

The Journal of Clinical Endocrinology & Metabolism · 18.12.2024 · 110 (1) · 254-262

DOI: 10.1210/clinem/dgae379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 31.05.2024. Verfasst von Eslam Montaser und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Blood Glucose Self-Monitoring, Blood Glucose, Disease Progression. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institute of Allergy and Infectious Diseases, University of Virginia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Static measures of continuous glucose monitoring (CGM) data, such as time spent in specific glucose ranges (70-180 mg/dL or 70-140 mg/dL), do not fully capture the dynamic nature of blood glucose, particularly the subtle gradual deterioration of glycemic control over time in individuals with early-stage type 1 diabetes.

Objective

Develop a diabetes diagnostic tool based on 2 markers of CGM dynamics: CGM entropy rate (ER) and Poincaré plot (PP) ellipse area (S).

Methods

A total of 5754 daily CGM profiles from 843 individuals with type 1, type 2 diabetes, or healthy individuals with or without islet autoantibody status were used to compute 2 individual dynamic markers: ER (in bits per transition; BPT) of daily probability matrices describing CGM transitions between 8 glycemic states, and the area S (mg2/dL2) of individual CGM PP ellipses using standard PP descriptors. The Youden index was used to determine “optimal” cut-points for ER and S for health vs diabetes (case 1); type 1 vs type 2 (case 2); and low vs high type 1 immunological risk (case 3). The markers’ discriminative power was assessed through the area under the receiver operating characteristics curves (AUC).

Results

Optimal cutoff points were determined for ER and S for each of the 3 cases. ER and S discriminated case 1 with AUC = 0.98 (95% CI, 0.97-0.99) and AUC = 0.99 (95% CI, 0.99-1.00), respectively (cutoffs ERcase1 = 0.76 BPT, Scase1 = 1993.91 mg2/dL2), case 2 with AUC = 0.81 (95% CI, 0.77-0.84) and AUC = 0.76 (95% CI, 0.72-0.81), respectively (ERcase2 = 1.00 BPT, Scase2 = 5112.98 mg2/dL2), and case 3 with AUC = 0.72 (95% CI, 0.58-0.86), and AUC = 0.66 (95% CI, 0.47-0.86), respectively (ERcase3 = 0.52 BPT, Scase3 = 923.65 mg2/dL2).

Conclusion

CGM dynamics markers can be an alternative to fasting plasma glucose or glucose tolerance testing to identify individuals at higher immunological risk of progressing to type 1 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Blood Glucose Self-MonitoringBlood GlucoseDisease ProgressionDiabetes Mellitus, Type 2BiomarkersHumansMaleFemaleAdultMiddle AgedYoung AdultAdolescentChildContinuous Glucose Monitoring

Stichwörter der Autor:innen

Poincaré plotcontinuous glucose monitoringentropy rateislet autoantibodiesstages of diabetestransition probability matrix

Substanzen

Blood GlucoseBiomarkers

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  • Center for Diabetes Technology, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
  • Division of Endocrinology and Metabolism, Department of Medicine, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.

ORCID-Profile: Eslam Montaser, Leon S Farhy, Boris P Kovatchev

Förderung

  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • University of Virginia
  • Commonwealth Research Commercialization Fund
  • NIDDK NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the JDRF
  • Dexcom, Inc
  • NIH

Zitieren

APA

Montaser, E., Farhy, L. S., & Kovatchev, B. P. (2024). Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics. The Journal of Clinical Endocrinology & Metabolism, 110(1), 254-262. https://doi.org/10.1210/clinem/dgae379

Vancouver

Montaser E, Farhy LS, Kovatchev BP. Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics. The Journal of Clinical Endocrinology & Metabolism. 2024;110(1):254-262. doi:10.1210/clinem/dgae379

BibTeX
@article{Montaser2024,
  author = {Montaser, Eslam and Farhy, Leon S and Kovatchev, Boris P},
  title = {Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {110},
  number = {1},
  pages = {254--262},
  doi = {10.1210/clinem/dgae379}
}
Kostenlos starten →